Phase II study of first-line sagopilone plus prednisone in patients with castration-resistant prostate cancer: a phase II study of the Department of Defense Prostate Cancer Clinical Trials Consortium

BACKGROUND: Preclinical studies in prostate cancer (PC) models demonstrated the anti-tumour activity of the first fully synthetic epothilone, sagopilone. This is the first study to investigate the activity and safety of sagopilone in patients with metastatic castration-resistant PC (CRPC). METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Beer, T M, Smith, D C, Hussain, A, Alonso, M, Wang, J, Giurescu, M, Roth, K, Wang, Y
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2012
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3425976/
https://www.ncbi.nlm.nih.gov/pubmed/22850553
http://dx.doi.org/10.1038/bjc.2012.339

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3425976/
https://www.ncbi.nlm.nih.gov/pubmed/22850553
http://dx.doi.org/10.1038/bjc.2012.339

Ejemplares similares